Find Varespladib Methyl manufacturers, exporters & distributors on PharmaCompass

Varespladib Methyl

Varespladib Methyl

Synopsis, Chemistry

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 172733-08-3, Ly333013, Ly-333013, A-002, Varespladib methyl ester, S-3013

Molecular Formula

C₂₂H₂₂N₂O₅

Molecular Weight

394.4 g/mol

InChI Key

VJYDOJXJUCJUHL-UHFFFAOYSA-N

FDA UNII

0NB98NBX3D

Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

1 2D Structure

Varespladib Methyl

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate

2.1.2 InChI

InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)

2.1.3 InChI Key

VJYDOJXJUCJUHL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N

2.2 Other Identifiers

2.2.1 UNII

0NB98NBX3D

2.3 Synonyms

2.3.1 MeSH Synonyms

1. A-002

2. Ly-333013

3. Ly333013

4. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate

5. S-3013

6. S3013

2.3.2 Depositor-Supplied Synonyms

1. 172733-08-3

2. Ly333013

3. Ly-333013

4. A-002

5. Varespladib Methyl Ester

6. S-3013

7. Varespladib Methyl [usan]

8. 0nb98nbx3d

9. Ly 333013

10. S 3013

11. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate

12. Varespladib Methyl (usan)

13. Methyl ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1h-indol-4-yl}oxy)acetate

14. Methyl-varespladib

15. Acetic Acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)-, Methyl Ester

16. Methyl 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate

17. Unii-0nb98nbx3d

18. Methyl Varespladib

19. Varespladib-methyl

20. Schembl25678

21. Chembl2105659

22. Dtxsid40938196

23. Chebi:192805

24. Xga73308

25. Zinc1550156

26. Varespladib Methyl Ester [mi]

27. Akos037643560

28. Cs-6574

29. Db05737

30. Sb16537

31. Ncgc00387871-03

32. As-16898

33. Hy-17448

34. D08221

35. Q7915615

36. Methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate

37. Methyl ((3-(aminooxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₂N₂O₅
Molecular Weight	394.4 g/mol
XLogP3	3.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	9
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	101
Heavy Atom Count	29
Formal Charge	0
Complexity	604
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in atherosclerosis and coronary artery disease.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Phospholipase A2 Inhibitors

Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme. (See all compounds classified as Phospholipase A2 Inhibitors.)

5.2 Mechanism of Action

A002 is an orally administered potent inhibitor of secretory phospholipase spla2(spla2) including groups IIA V and X. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. spla2 levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke.